Ultrasound Technology Developed at U-M Now in Clinical Trials for Liver Cancer

Trial will evaluate the safety and efficacy of histotripsy against liver tumors at eight U.S. sites.

5:00 AM

Author | Ian Demsky

Color wires Microsopic Tissue Ultrasonic waves
Illustration of histotripsy technology. Image courtesy of Medicine at Michigan Magazine.

The University of Michigan is one of eight sites around the country that will enroll patients in a clinical trial to evaluate the safety and efficacy of a technology that uses ultrasound to treat liver tumors.

The #HOPE4LIVER trial will employ the noninvasive technique to mechanically destroy primary and metastatic liver tumors.

The technology, called histotripsy, was developed by U-M researchers over more than 15 years and is being commercialized by a U-M startup company, HistoSonics, which is sponsoring the trial.

Using ultrasonic pulses is nothing new to medicine, but the process behind histotripsy is. While previous techniques use heat energy to ablate tissues, histotripsy harnesses the energy of thousands of microbubbles — called cavitation — to emulsify tissue. And it can do so with great precision, narrowly targeting the tissues of interest.

Interventional radiologist Mishal Mendiratta-Lala, M.D., who specializes in the diagnosis and treatment of liver cancer and other abdominal cancers, is principal investigator of the U-M trial site.

MORE FROM THE LAB: Subscribe to our weekly newsletter

"We are very excited to help move this technology out of the laboratory and into a clinical trial where we can evaluate its safety and efficacy for patients," she says. "Preclinical models have been very encouraging regarding the technology's ability not only to destroy tumors non-invasively, but also to stimulate the body's immune response to cancer."

As a researcher, Mendiratta-Lala has worked closely with one of the technology's principal inventors, Zhen Xu, Ph.D., a professor of biomedical engineering at U-M, to analyze histotripsy's impact in animal models of liver cancer.

We are very excited to help move this technology out of the laboratory and into a clinical trial where we can evaluate its safety and efficacy for patients.
Mishal Mendiratta-Lala, M.D.

HistoSonics is also conducting clinical trials of the technology in Europe and hopes to expand the use of its platform to other types of solid tumors after the U.S. liver study.

"Anyone close to the field of therapeutic ultrasound knows that the novel science of histotripsy was born from the work of an incredible team of researchers at U-M," says Mike Blue, HistoSonics' president and CEO. "It is only fitting that our collaborating U-M physicians and the hospital are a part of this trial and represent the science that that they discovered and developed alongside the company over the past decade. We could not be happier for everyone who has played a role in getting this platform to where it is today, especially the early inventors and company cofounders."

Meanwhile, histotripsy has also shown promise toward improving immunotherapy.

A study from the lab of U-M surgeon Clifford Cho, M.D., published last year in the Journal for ImmunoThearpy of Cancer, found histotripsy ablation magnified the effect of checkpoint inhibition immunotherapy in mouse models of melanoma and hepatocellular carcinoma.

Disclosures: U-M retains a financial stake in HistoSonics, as do a number of researchers who helped to develop the technology, and each stand to benefit financially from the success of the platform. Serving in the capacity of a paid consultant to the company, Cho is co-principal investigator of the national trial to treat liver tumors in humans; as one of the original researchers into the technology, he also has a financial interest in it.

Like Podcasts? Add the Michigan Medicine News Break on iTunes or anywhere you listen to podcasts.


More Articles About: Health Tech Cancer Research Liver Cancer Clinical Trials Cancer: Help, Diagnosis & Treatment
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories purple white
Health Lab
Study defines key driver of aggressive ovarian cancer
A study explains the genetic underpinnings of a rare and aggressive form of ovarian cancer – and offers a potential pathway for new treatments.
Cancer Aware surrounded by a circle of multicolor ribbons
Cancer Aware
University of Michigan’s Impact on the Future of Cancer Care
Four University of Michigan faculty members have served as president of the American Society of Clinical Oncology, a rare distinction that only two other institutions can claim. ASCO is the world's leading professional organization for physicians and oncology professionals caring for people with cancer. In this episode, Nicole Fawcett, director of communications for the Rogel Cancer Center, sat down with four past ASCO Presidents and talked about the importance of the society, the impact it has had on cancer care and research as a whole and the impact here at U-M. Participants: Allen Lichter, MD, FASTRO Doug Blayney, MD Dan Hayes, MD Lori Pierce, MD
pill being taken close up with water near hand
Health Lab
Patients are opting in for 10 years of breast cancer treatment
As recommendations suggest extending hormone-based breast cancer treatment to 10 years for some patients, a recent study sheds light on whether patients are opting for it.
cells spikey on pink background purple spikes
Health Lab
New clinical trials for pediatric brain tumors
Brain and spinal cord tumors account for one in four childhood cancers. Although 75% of children survive for at least five years after being diagnosed, many patients have recurrent tumors that cannot be cured. Andrea Franson discusses current therapies for pediatric brain tumors, how viruses can be used to target tumor cells and the new phase 1 trial that started in May 2025.
red background person laying on ground with machine over looking into body organs appearing on screen
Health Lab
Histotripsy stimulates the immune system to attack cancer cells outside the liver
The University of Michigan Health pioneered the treatment histotripsy for liver cancer, which is helping teach the immune system which cancer cells to attack.
cells purple some lighter cells in white
Health Lab
Researchers find early driver of prostate cancer aggressiveness
University of Michigan Health Rogel Cancer Center scientists identified a gene that plays a key role in prostate cancer cells that have transitioned to a more aggressive, treatment-resistant form. The gene can be indirectly targeted with an existing class of drugs, suggesting a potential treatment strategy for patients with aggressive subtypes of prostate cancer.